SK bioscience announced on the 4th that it has signed a supply contract for influenza (flu) vaccines with the Public Procurement Service for the 2025-2026 season. The contract amount is 22.728 billion won, which corresponds to 8.5% of last year's sales of 267.545 billion won.
The sales and supply area is nationwide, and the contract will end on June 30, 2026. The company added that the Korea Disease Control and Prevention Agency, the demand agency, can change the contract according to quantity fluctuations within 10% of the contracted amount.
In 2015, SK bioscience launched "Skycellflu," the first cell-cultured influenza vaccine in Korea, and followed it with "Skycellflu quadrivalent," the world's first vaccine that prevents four types of influenza viruses. Currently, it is supplying this vaccine to countries in the southern hemisphere, including Southeast Asia and Latin America.